Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Obstetrics/Gynecology (Women’s Health) | Oncology | Family Medicine
Search Medical Condition
Fallopian Tube Cancer Clinical Trials
A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (116) clinical trials
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is an open label study, active-controlled, multi-center study. The total duration of the study will be approximately 64 months. The screening phase may last up to 30 days. If the results of the procedures done during the screening period allow study participation, there will be randomization into 1 of ...
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
You are being asked to take part in this study because you have high grade serous ovarian primary peritoneal or fallopian tube cancer. Standard chemotherapy for your type of cancer usually consists of two drugs called carboplatin and paclitaxel. This treatment has been found to be effective, but many subjects ...
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00719303?term=GOG+0225&rank=1
GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01366183?term=GOG+0273&rank=1
GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB.
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00565851?term=gog+0213&rank=1
Ovarian, Fallopian Tube or Peritoneal Cancer
Winthrop University Hospital Gynecologic Oncology Department is seeking volunteers who have been diagnosed with Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer and are willing to participate in a clinical research study to see if an investigational vaccine is safe and effective. Eligible participants will receive the ...
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian Fallopian Tube or Primary Peritoneal Cancer Undergoing Surgery
PRIMARY OBJECTIVES: I. Determine whether the addition of an IGFBP-2 vaccine to neoadjuvant chemotherapy increases the rate of complete pathologic response (CR). SECONDARY OBJECTIVES: I. Determine whether the addition of an IGFBP-2 vaccine to neoadjuvant chemotherapy increases progression free survival at 12 months. II. Determine whether the addition of an ...
Pembrolizumab Bevacizumab and Cyclophosphamide in Treating Patients With Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
PRIMARY OBJECTIVES: I. To evaluate improvement in progression-free survival for patients treated with anti-programmed cell death 1 (anti-PD1) pembrolizumab in combination with intravenous (IV) bevacizumab and oral metronomic cyclophosphamide as compared to patients treated with other second line chemotherapeutic agents. SECONDARY OBJECTIVES: I. To obtain pilot data on clinical response ...
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian Fallopian or Peritoneal Cancer
PRIMARY OBJECTIVES: I. Compare clinical efficacy of Arm A (MV-NIS therapy) and Arm B (standard cytotoxic chemotherapy), as measured by overall survival (OS). SECONDARY OBJECTIVES: I. Compare progression-free survival (PFS), overall survival at 12 months (OS12), progression-free survival at six months (PFS6), and objective response rate (ORR) between MV-NIS therapy ...
DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission
PRIMARY OBJECTIVES: I. To determine the safety of fixed doses of DEC205mAb-NY-ESO-1 fusion protein (DEC-205/NY-ESO-1 fusion protein CDX-1401) with adjuvant poly-ICLC given as a vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To evaluate toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...
